

A nighttime photograph of a cityscape featuring palm trees in the foreground, a body of water reflecting city lights, and various buildings in the background, including a church with a steeple. A large, semi-transparent blue triangle is overlaid on the left side of the image.

APSARD 2023

Program Book

BOARD OF DIRECTORS



Ann Childress, M.D.

President

Psychiatrist Center for
Psychiatry and Behavioral
Medicine, Inc.



Gregory Mattingly, M.D.

President Elect

Washington University
School of Medicine



Jeffrey Newcorn, M.D.

Past President


Mt. Sinai Medical Center



David Goodman, M.D.

Treasurer

Johns Hopkins School of
Medicine



Margaret Sibley, Ph.D.

Secretary

University of Washington
School of Medicine

BOARD MEMBERS

Maria Acosta, M.D.*

NHGRI/NIH

**Dr. Acosta is serving in a personal capacity*

Mark Bertin, M.D.

New York Medical College

Sam Goldstein, Ph.D.

PosJournal of Attention Disorders

Frances Levin, M.D.

Columbia University

Joel Nigg, Ph.D.

Center for ADHD Research at Oregon
Health & Science University

Erin Schoenfelder Gonzalez, Ph.D.

University of Washington

Mark Stein, Ph.D.

University of Washington

Anne Arnett, Ph.D.

Boston Children's Hospital/Harvard
Medical School

Thomas Brown, Ph.D.

Keck School of Medicine of University
of Southern California

**Martin Katzman, M.D., B.Sc.,
FRCP(C)**

START Clinic for Mood and Anxiety Disorders

Keith McBurnett, Ph.D.

University of California, San Francisco

Keri Rosch, Ph.D.

Center for Neurodevelopmental and Imaging
Research at Kennedy Krieger Institute

Julie Schweitzer, Ph.D.

MIND Institute, UC Davis School of Medicine

James Waxmonsky, M.D.

Penn State College of Medicine

Jacob Behrens, M.D.

Envision ADHD

J Faye Dixon, Ph.D.

UC Davis Medical Center

Beth Krone, Ph.D.

Clinical Research Coordinator-Post Doc
School of Medicine at Mount Sinai

Brooke Molina, Ph.D.

Professor of Psychiatry, Psychology, and
Pediatrics University of Pittsburgh

Douglas Russell, M.D.

University of Washington / Seattle Children's

Philip Shaw, Ph.D.

National Human Genome Research Institute*
**Dr. Shaw is serving in a personal capacity*

Cathi Zillman, PMHNP, CPNP

South Shore Child Guidance Center

Thank you!

DEPARTING BOARD MEMBERS

APSARD would not be successful without the hard work of our board members. We are grateful for their time, dedication and passion for better the field of ADHD and related disorders.

To our departing board members, thank you for your commitment to APSARD, we look forward to growing your legacy.

Maria Acosta, M.D.*

NHGRI/NIH

**Dr. Acosta is serving in a personal capacity*

Joel Nigg, Ph.D.

Center for ADHD Research at Oregon
Health & Science University

Keith McBurnett, Ph.D.

University of California, San Francisco

Thomas Brown, Ph.D.

Keck School of Medicine of University
of Southern California

2023 PROGRAM COMMITTEE

Co-Chair

Brooke Molina, Ph.D.

University of Pittsburgh

Co-Chair

Frances Levin, M.D.

Columbia University Medical Center

Ann Childress, M.D.

Psychiatrist Center for Psychiatry and
Behavioral Medicine, Inc.

Jeffrey Newcorn, M.D.

Icahn School of Medicine at
Mount Sinai

Gregory Mattingly, M.D.

Washington University School of Medicine

Margaret Sibley, Ph.D.

University of Washington School of Medicine

Margaret Weiss, MD, PhD, FRCP(C)

Cambridge Health Alliance

Steven Pliszka, M.D.

University of Texas San Antonio

Joel Nigg, Ph.D.

Oregon Health & Science University

John Mitchell, Ph.D.

Duke University Medical Center

Mariely Hernandez, Ph.D.

Columbia University Medical Center

**Martin Katzman, M.D., B.Sc.,
FRCP(C)**

START Clinic for Mood and Anxiety Disorders

**Join us to hear viewpoints
from multiple perspectives
on adult ADHD treatment**



**SATURDAY, JANUARY 14TH
2:30-3:30 PM**

**Renaissance Orlando
SeaWorld, Peninsula 4**

Clinical Conundrum: Appropriate Use of Stimulant Medications in Adults With ADHD



Greg Mattingly, MD

St. Charles Psychiatric Associates
Washington University



Oren Mason, MD

Attention MD
Grand Rapids, MI



**VISIT THE
BOOTH!**

A NOVEL, NONSTIMULANT APPROACH IN ADULT ADHD^{1,2}

Less chaos...
More control^{1,3}



Patient portrayals.

ADHD does not need to get in the way of adulting

Supernus Pharmaceuticals proudly supports the 2023 APSARD Annual Conference.

INDICATION

Qelbree is indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors.

CONTRAINDICATIONS

- Concomitant administration of a monoamine oxidase inhibitor (MAOI), or dosing within 14 days after discontinuing an MAOI, because of an increased risk of hypertensive crisis
- Concomitant administration of sensitive CYP1A2 substrates or CYP1A2 substrates with a narrow therapeutic range

WARNINGS & PRECAUTIONS

- *Suicidal thoughts and behaviors:* Closely monitor all Qelbree-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes

Abbreviations: ADHD, attention-deficit/hyperactivity disorder; APSARD, The American Professional Society of ADHD and Related Disorders.

REFERENCES: 1. Qelbree [package insert]. Rockville, MD: Supernus Pharmaceuticals, Inc. 2. Food and Drug Administration. Novel drug approvals for 2021. May 13, 2022. Accessed June 13, 2022. <https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021>. 3. Adler L, Spencer T, Biederman MD. Adult ADHD Investigator Symptom Rating Scale (AISRS). Massachusetts General Hospital and New York University School of Medicine; 2010.

Please see the full [Prescribing Information](#), including Boxed Warning at [QelbreeHCP.com](#).

Qelbree[®] ONCE-DAILY
viloxazine
extended-release capsules
100 mg 150 mg 200 mg
Rethink ADHD Symptom Control



Qelbree and Rethink ADHD Symptom Control are registered trademarks of Supernus Pharmaceuticals, Inc.
©2022 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2022-0347

A Medscape **LIVE!** EVENT

CME/CNE/CPE

Don't Let ADHD Fly Under the Radar

Recognition and Treatment of ADHD in the Context of Comorbidity

FRIDAY, JANUARY 13, 2023 | 1:00 PM – 2:00 PM ET

REGISTRATION AND MEAL: 12:30 PM | PRESENTATION: 1:00 PM

RENAISSANCE ORLANDO AT SEA WORLD, 6677 SEA HARBOR DRIVE
ORLANDO, FLORIDA | PENINSULA 4



MODERATOR



Ann Childress, MD
President
Center for Psychiatry
and Behavioral Medicine, Inc.
President, APSARD - American Professional
Society for ADHD and Related Disorders
Las Vegas, Nevada

PANELISTS



Vladimir Maletic, MD, MS
Clinical Professor of Psychiatry
USC School of Medicine
Greenville, South Carolina



Gregory W. Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
President, Midwest Research Group
President Elect, APSARD - American
Professional Society for ADHD
and Related Disorders
St. Louis, Missouri



For more information and to register, visit:
www.medscape.org/townhall/adhd-radar

Supported by an independent educational
grant from Supernus Pharmaceuticals, Inc.

Medscape
EDUCATION



Do your adult patients desire flexibility from their ADHD medication?

JOIN US FOR A BREAKFAST PRESENTATION:



A Tailored Treatment for Adults With ADHD

Speaker: Greg Mattingly, MD

Date: Saturday

Time: 8:00 AM - 9:00 AM

Dr. Gregory Mattingly, MD: Associate Clinical Professor, Washington University; President, Midwest Research Group; President Elect, American Professional Society for ADHD and Related Disorders (APSARD). Dr. Mattingly is a paid consultant of Noven Pharmaceuticals, Inc.

And visit us at our booths to learn more about Noven's mission to improve patients' lives with transdermal drug delivery systems.



©2023 Noven Therapeutics, LLC.
All rights reserved.
XEL-2106-16 01/2023

APSARD SPECIAL INTEREST GROUPS

Networking has never been so easy! Introducing the newest APSARD Member Benefit, Special Interest Groups (SIGs). Join the conversations today with like-minded APSARD professionals.

APSARD is thrilled to introduce Special Interest Groups (SIGs) as a new member benefit! Special Interest Groups help establish better relationships, enable networking, and information exchange. Through the leadership of our dedicated SIG

Co-Chairs, members with shared interests will have the opportunity to meet and discuss ideas, trends, issues, and thoughts. We hope that all of our members will find at least one of our inaugural SIGs to participate in!

You can learn more about each SIG Group on our website [HERE](#).

Our inaugural SIGs are:

- College Students & ADHD
- ADHD & Substance Use Disorders
- Pediatrics-Psychiatry Interface
- Women & Girls with ADHD
- Technology & ADHD

For additional information please email the Executive Office at info@apsard.org



APSARD

The American Professional Society
of ADHD and Related Disorders



Thank You!

2023 SPONSORS & EXHIBITORS

We are grateful for the generous support of our sponsors and exhibitors!



serdexmethylphenidate
and dexamethylphenidate

26.1/5.2mg • 39.2/7.8mg • 52.3/10.4mg capsules

NOVEN

Qbtech



AKILI



Otsuka



NEUROSYNC



IRONSHORE

OYSTA



Duke Center for Girls & Women
with ADHD



Tris
P H A R M A



Supernus[®]
Pharmaceuticals